They found 36.4% of men in the phi group were biopsied compared to 60.3% of those in the non-phi cohort. While phi testing scores influenced biopsy deferrals, as well as decisions to perform biopsies, all in all, use of the testing resulted in a net 24% reduction in biopsies, according to the study.
“It was remarkable to see the rate of biopsy drop so significantly without changing the rate of prostate cancer detection. In other words, there was a significant reduction in the rate of unnecessary biopsy procedures as a result of better informed patient selection,” Dr. White said.
phi scores influenced urologists’ patient management plans in 73% of cases, after consideration of other clinical factors, according to the study. And 92% of the urologists’ responses suggested the phi score was a helpful communication tool with patients and a potential anxiety-reducer when scores were low.
Careful identification of patients is very important, according to Dr. White.
“The test performs very well in men 50 years of age and older with total PSA between 4.0 and 10.0 ng/mL concomitant with negative digital rectal exam findings,” he said. “As with any laboratory result, it cannot be acted upon in isolation and must be considered along with the patient’s clinical risk factors and family history to determine how best to manage the patient.”
This study doesn’t include randomization and longitudinal follow-up, which should be addressed in future studies, according to the authors.
“I think it is the tip of the iceberg with respect to improving the screening of men for prostate cancer, while controlling costs to the patient and the health care system at large. I'm very excited about gathering longitudinal follow-up data so that we can analyze long-term outcomes in men tested with phi,” Dr. White said.
More from Urology Times:
To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.